Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Altamira Therapeutics

Altamira Therapeutics Secures Marketing & Distribution Agreements To Expand Sales Channels of Bentrio into Egypt and Pakistan
From Altamira Therapeutics
Via AccessWire
Tickers CYTO
Altamira Therapeutics Receives FDA 510(k) Clearance for Bentrio to Treat Allergic Rhinitis
From Altamira Therapeutics
Via AccessWire
Tickers CYTO
Altamira Therapeutics Achieves COVAMID Trial Target Enrollment for Bentrio in Acute COVID-19
From Altamira Therapeutics
Via AccessWire
Tickers CYTO
Altamira Therapeutics Receives NASDAQ Notification Regarding Minimum Bid Requirements
From Altamira Therapeutics
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers CYTO
Altamira Therapeutics Reports 89.5% and 98.9% Reduction in Viral Load Against Human Rhinovirus With its Bentrio Nasal Spray
From Altamira Therapeutics
Via AccessWire
Tickers CYTO
Altamira Therapeutics Announces Marketing Approval for Bentrio Nasal Spray in Indonesia
From Altamira Therapeutics
Via AccessWire
Tickers CYTO
Altamira Therapeutics Receives Philippines' FDA Approval of Bentrio Nasal Spray
From Altamira Therapeutics
Via AccessWire
Tickers CYTO
Altamira Therapeutics Announces Positive Top-line Results from its Clinical Trial with Bentrio Nasal Spray in House Dust Mite Study
From Altamira Therapeutics
Via AccessWire
Tickers CYTO
Altamira Therapeutics to Present at the 2022 H.C. Wainwright Global Investment Conference
From Altamira Therapeutics
Via AccessWire
Tickers CYTO
Altamira Therapeutics Issues Shareholder Letter
From Altamira Therapeutics
Via AccessWire
Tickers CYTO
Altamira Receives Regulatory Approval from the Ministry of Health to Expand COVAMID Trial for Bentrio in Acute COVID-19 into North Macedonia
From Altamira Therapeutics
Via AccessWire
Tickers CYTO
Altamira Reaches COVAMID Trial Enrollment Midpoint for Bentrio in Acute COVID-19
From Altamira Therapeutics
Via AccessWire
Tickers CYTO
Altamira Therapeutics Provides Business Update and Reports Second Half and Full Year 2021 Financial Results
From Altamira Therapeutics
Via AccessWire
Tickers CYTO
Altamira Therapeutics Announces Peer-Reviewed Publication on Positive in vitro Data with its Bentrio(TM) Drug-Free Nasal Spray Against SARS-CoV-2 Delta Variant
From Altamira Therapeutics
Via AccessWire
Tickers CYTO
Altamira Therapeutics Sets Full Year 2021 Earnings Call for Tuesday, April 12, 2022, 8:00 a.m. ET
From Altamira Therapeutics
Via AccessWire
Topics Earnings
Tickers CYTO
Altamira Therapeutics Completes Patient Enrollment in House Dust Mite Allergy Trial with Bentrio
From Altamira Therapeutics
Via AccessWire
Tickers CYTO
Altamira Therapeutics Reports Positive In Vitro Efficacy Data for Bentrio Nasal Spray in Protecting Against Sars-CoV-2 Omicron Variant
From Altamira Therapeutics
Via AccessWire
Tickers CYTO
Altamira Therapeutics Receives Approval to Commence Clinical Trial Evaluating Bentrio in the Treatment of COVID-19
From Altamira Therapeutics
Via AccessWire
Tickers CYTO
Altamira Therapeutics and Nuance Pharma Enter Into Exclusive Licensing and Distribution Agreement for Bentrio in China and Additional Asian Markets
From Altamira Therapeutics
Via AccessWire
Tickers CYTO
Altamira Therapeutics Completes Final Patient Enrollment in Phase 2 'TRAVERS' Clinical Trial of AM-125 for the Treatment of Acute Vertigo
From Altamira Therapeutics
Via AccessWire
Tickers CYTO
Altamira Therapeutics and Wellesta Expand Bentrio Marketing and Distribution Agreement to Include Two Additional Markets
From Altamira Therapeutics
Via AccessWire
Tickers CYTO
Altamira Therapeutics and Avernus Pharma Collaborate for Marketing and Distribution of Bentrio in Gulf Countries
From Altamira Therapeutics
Via AccessWire
Tickers CYTO
Altamira Therapeutics Establishes OTC Consumer Health Business Unit
From Altamira Therapeutics
Via AccessWire
Tickers CYTO
Altamira Therapeutics Announces Approval of Bentrio Nasal Spray in Malaysia
From Altamira Therapeutics
Via AccessWire
Tickers CYTO
Altamira Therapeutics Provides Update on RNA Therapeutics Program
From Altamira Therapeutics
Via AccessWire
Tickers CYTO
Altamira Therapeutics to Participate in the H.C. Wainwright BioConnect Virtual Conference
From Altamira Therapeutics
Via AccessWire
Tickers CYTO
Altamira Therapeutics Provides Update on Bentrio Program
From Altamira Therapeutics
Via AccessWire
Tickers CYTO
Altamira Therapeutics Announces Randomization of First Patients in Bentrio Trial in House Dust Mite Allergy
From Altamira Therapeutics
Via AccessWire
Tickers CYTO
Altamira Therapeutics Announces Randomization of First Patient in Bentrio Trial in Seasonal Allergic Rhinitis
From Altamira Therapeutics
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers CYTO
Altamira Therapeutics Announces Poster Presentations at AHA Scientific Sessions 2021
From Altamira Therapeutics
Via AccessWire
Topics Death Intellectual Property Regulatory Compliance
Tickers CYTO
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.